SAFETY AND TOLERABILITY CHARACTERIZATION OF MARALIXIBAT IN INFANTS WITH ALGS FROM 2 MONTHS OF AGE: INTERIM RESULTS FROM THE RISE STUDY

被引：0
|
作者：
Gonzales, Emmanuel [1 ,2 ]
Jankowska, Irena [3 ]
Horslen, Simon P. [4 ]
Ekong, Udeme [5 ]
Rosenthal, Philip [6 ]
Sokal, Etienne [7 ]
Lin, Chuan-Hao [8 ]
Garner, Will [9 ]
Elliott, Jilliann [9 ]
Nunes, Tiago [9 ]
Thompson, Richard J. [10 ]
机构：
[1] Univ Paris Saclay, Inserm Umr 1193, Hepatinov, Orsay, France
[2] Univ Paris Saclay, Hop Bicetre, AP HP, Ctr Reference Natl Atresie Voies Biliaires & Chol, Le Kremlin Bicetre, France
[3] Childrens Mem Hlth Inst, Gastroenterol Hepatol Nutr Disorders & Paediat, Warsaw, Poland
[4] UPMC Childrens Hosp Pittsburgh, Pediat, Pittsburgh, PA USA
[5] Medstar Georgetown Univ Hosp, Medstar Georgetown Transplant Inst, Washington, DC USA
[6] Univ Calif San Francisco, Div Pediat Gastroenterol Hepatol & Nutr, Pediat, San Francisco, CA USA
[7] Clin Univ St Luc, Uclouvian, Pediat Hepatol, Brussels, Belgium
[8] Childrens Hosp Angeles, Los Angeles, CA USA
[9] Mirum Pharmaceut Inc, Foster City, CA USA
[10] Kings Coll London, Inst Liver Studies, London, England
来源：
HEPATOLOGY | 2023年 / 77卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
5021
引用
收藏
页码：E135 / E135
页数：1
相关论文
共 50 条
  • [1] Facilitated subcutaneous immunoglobulin 10% for CIDP: interim results from a long-term safety and tolerability study
    Hadden, R.
    Andersen, H.
    Bril, V.
    Basta, I.
    Rejdak, K.
    Djordjevic, G.
    Greco, E.
    Hasan, S.
    French, J.
    Yel, L.
    Ay, H.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 286 - 286
  • [2] Interim Efficacy and Safety Results from the Phase 2 NURTURE Study Evaluating Nusinersen in Presymptomatic Infants with Spinal Muscular Atrophy
    De Vivo, Darryl C.
    Hwu, Wuh-Liang
    Reyna, Sandra P.
    Farwell, Wildon
    Gheuens, Sarah
    Sun, Peng
    Zhong, Zhenshao John
    Su, John
    Schneider, Eugene
    Bertini, Enrico
    NEUROLOGY, 2017, 88
  • [3] NUTRITION OF FRENCH INFANTS FROM 2 TO 9 MONTHS OF AGE
    LESTRADET, H
    MACHINOT, S
    GRENECHE, MO
    DUFOUR, C
    SIX, MF
    REVUE DE PEDIATRIE, 1979, 15 (01): : 11 - 20
  • [4] Mealtime communication patterns of infants from 2 to 24 months of age
    Skinner, JD
    Carruth, BR
    Houck, K
    Moran, J
    Reed, A
    Coletta, F
    Ott, D
    JOURNAL OF NUTRITION EDUCATION, 1998, 30 (01): : 8 - 16
  • [5] Safety and efficacy of efpegerglucagon in patients with congenital hyperinsulinism: interim results from a phase 2 study
    Dastamani, Antonia
    Banerjee, Indraneel
    Mohnike, Klaus
    Puri, Mala
    Gwak, Eunji
    Kang, Seohyun
    Byeon, JinHee
    Lee, Moon Hee
    De Leon, Diva
    HORMONE RESEARCH IN PAEDIATRICS, 2024, 97 : 319 - 319
  • [6] PHYSICAL GROWTH OF INFANTS 7 TO 13 MONTHS OF AGE - RESULTS FROM A NATIONAL SURVEY
    RYAN, AS
    MARTINEZ, GA
    AMERICAN JOURNAL OF PHYSICAL ANTHROPOLOGY, 1987, 73 (04) : 449 - 457
  • [7] Safety of levetiracetam among infants younger than 12 months - Results from a European multicenter observational study
    Arzimanoglou, Alexis
    Loesch, Christian
    Garate, Pablo
    Bentz, Jurgen
    EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2016, 20 (03) : 368 - 375
  • [8] Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study
    De Vivo, Darryl C.
    Bertini, Enrico
    Swoboda, Kathryn J.
    Hwu, Wuh-Liang
    Crawford, Thomas O.
    Finkel, Richard S.
    Kirschner, Janbernd
    Kuntz, Nancy L.
    Parsons, Julie A.
    Ryan, Monique M.
    Butterfield, Russell J.
    Topaloglu, Haluk
    Ben-Omran, Tawfeg
    Sansone, Valeria A.
    Jong, Yuh-Jyh
    Shu, Francy
    Staropoli, John F.
    Kerr, Douglas
    Sandrock, Alfred W.
    Stebbins, Christopher
    Petrillo, Marco
    Braley, Gabriel
    Johnson, Kristina
    Foster, Richard
    Gheuens, Sarah
    Bhan, Ishir
    Reyna, Sandra P.
    Fradette, Stephanie
    Farwell, Wildon
    NEUROMUSCULAR DISORDERS, 2019, 29 (11) : 842 - 856
  • [9] Safety and Tolerability of Bemdaneprocel in People with Parkinson's disease (PD): Results up to 24 Months from a Phase 1 Study
    Sarva, H.
    Henchcliffe, C.
    Lozano, A.
    Fasano, A.
    Kalia, S.
    Yu, K.
    Brennan, C.
    Stemple, W.
    Abid, N.
    Yountz, M.
    Enayetallah, A.
    Lampron, A.
    Tabar, V.
    MOVEMENT DISORDERS, 2024, 39 : S433 - S434
  • [10] Safety, Tolerability, and Clinical Assessment of Bemdaneprocel for Parkinson's Disease: Results up to 18 Months from a Phase 1 Study
    Henchcliffe, Claire
    Sarva, Harini
    Lozano, Andres
    Fasano, Alfonso
    Kalia, Suneil
    Yu, Kenny Kwok Hei
    Brennan, Cameron
    Stemple, Whitney
    Abid, Nauman
    Yountz, Marcus
    Enayetallah, Ahmed
    Lampron, Antoine
    Tabar, Viviane
    MOLECULAR THERAPY, 2024, 32 (04) : 130 - 130
12345